21-2697 (L) SL-X IP S.A.R.L. v. Bank of America Corporation
UNITED STATES COURT OF APPEALS FOR THE SECOND CIRCUIT
SUMMARY ORDER
RULINGS BY SUMMARY ORDER DO NOT HAVE PRECEDENTIAL EFFECT. CITATION TO A SUMMARY ORDER FILED ON OR AFTER JANUARY 1, 2007, IS PERMITTED AND IS GOVERNED BY FEDERAL RULE OF APPELLATE PROCEDURE 32.1 AND THIS COURT’S LOCAL RULE 32.1.1. WHEN CITING A SUMMARY ORDER IN A DOCUMENT FILED WITH THIS COURT, A PARTY MUST CITE EITHER THE FEDERAL APPENDIX OR AN ELECTRONIC DATABASE (WITH THE NOTATION “SUMMARY ORDER”). A PARTY CITING A SUMMARY ORDER MUST SERVE A COPY OF IT ON ANY PARTY NOT REPRESENTED BY COUNSEL.
1 At a stated term of the United States Court of Appeals for the Second Circuit, held at the 2 Thurgood Marshall United States Courthouse, 40 Foley Square, in the City of New York, on the 3 24th day of March, two thousand twenty-three. 4 5 PRESENT: 6 DENNIS JACOBS, 7 MYRNA PÉREZ, 8 SARAH A. L. MERRIAM, 9 Circuit Judges. 10 _____________________________________ 11 12 SL-X IP SA.R.L., SL-X Technology UK Ltd., SL- 13 X Technology USA LLC, SL-X Trading Europe 14 Ltd., and SL-X Trading USA LLC, 15 16 Plaintiffs-Appellants, 17 18 v. Nos. 21-2697, 21-2699 19 20 Merrill Lynch, Pierce, Fenner & Smith Inc., 21 Merrill Lynch L.P. Holdings, Inc., Merrill Lynch 22 Professional Clearing Corp., Credit Suisse AG, 23 Credit Suisse Securities (USA) LLC, Credit Suisse 24 First Boston Next Fund, Inc., Credit Suisse Prime 25 Securities Services (USA) LLC, Goldman Sachs & 26 Co. LLC, J.P. Morgan Securities LLC, J.P. 27 Morgan Prime, Inc., J.P. Morgan Strategic 28 Securities Lending Corp., J.P. Morgan Chase 29 Bank, N.A., Morgan Stanley & Co. LLC, Prime 30 Dealer Services Corp., Strategic Investments I,
1 1 Inc., UBS AG, UBS Americas Inc., UBS 2 Securities LLC, UBS Financial Services Inc., 3 EquiLend LLC, EquiLend Europe Ltd., EquiLend 4 Holdings LLC, 5 6 Defendants - Appellees, 7 8 Bank of America Corp., Goldman Sachs Group, 9 Inc., Goldman Sachs Execution & Clearing, L.P., 10 J.P. Morgan Chase & Co., J.P. Morgan 11 Institutional Investments Inc., UBS Group AG, 12 UBS Investment Bank, UBS Asset Management 13 (US) Inc., UBS Fund Services (USA) LLC, Credit 14 Suisse Group AG, Morgan Stanley, Morgan 15 Stanley Capital Management, LLC, Morgan 16 Stanley Distribution, Inc., 17 18 Defendants. * 19 20 _____________________________________ 21 22 FOR PLAINTIFFS-APPELLANTS: RISHI BHANDARI (Evan Mandel, Robert 23 Glunt, on the brief), Mandel Bhandari LLP, 24 New York, NY. 25 26 FOR DEFENDANTS-APPELLEES LAUREN M. ROSENBERG (Michael A. Paskin, 27 MORGAN STANLEY & CO. LLC, on the brief), Cravath, Swaine & Moore LLP, 28 PRIME DEALER SERVICES CORP., New York, NY. 29 AND STRATEGIC INVESTMENTS I, INC.: 30 31 FOR DEFENDANTS-APPELLEES Adam S. Hakki, Richard F. Schwed, Michael 32 MERRILL LYNCH, PIERCE, FENNER P. Mitchell, Shearman & Sterling LLP, New 33 & SMITH INC., MERRILL LYNCH L.P. York, NY and Washington, D.C. 34 HOLDINGS, INC., AND MERRILL LYNCH 35 PROFESSIONAL CLEARING CORP.: 36 37 FOR DEFENDANTS-APPELLEES David G. Januszewski, Herbert S. Washer, 38 CREDIT SUISSE AG, CREDIT SUISSE Elai Katz, Jason M. Hall, Margaret A. 39 SECURITIES (USA) LLC, CREDIT Barone, Cahill Gordon & Reindel LLP, 40 SUISSE FIRST BOSTON NEXT FUND, New York, NY. 41 INC., AND CREDIT SUISSE PRIME 42 SECURITIES SERVICES (USA) LLC:
* The Clerk of Court is respectfully directed to amend the case caption as set forth above.
2 1 FOR DEFENDANT-APPELLEE Robert Y. Sperling, George Mastoris, Staci 2 GOLDMAN SACHS & CO. LLC: Yablon, Winston & Strawn LLP, Chicago, 3 IL and New York, NY. 4 5 FOR DEFENDANTS-APPELLEES Robert D. Wick, Henry B. Liu, John S. 6 J.P. MORGAN SECURITIES LLC, J.P. Playforth, Jeffrey Cao, Covington & Burling 7 MORGAN PRIME, INC., J.P. MORGAN LLP, Washington, D.C. 8 STRATEGIC SECURITIES LENDING 9 CORP., AND J.P. MORGAN CHASE 10 BANK, N.A.: 11 12 FOR DEFENDANTS-APPELLEES Peter G. Wilson, Katten Muchin Rosenman 13 UBS AG, UBS AMERICAS INC., LLP, Chicago, IL. 14 UBS SECURITIES LLC, AND UBS 15 FINANCIAL SERVICES INC.: 16 17 FOR DEFENDANTS-APPELLEES Carmine D. Boccuzzi, Jr., Cleary Gottlieb 18 EQUILEND LLC, EQUILEND Steen & Hamilton LLP, New York, NY. 19 EUROPE LTD., AND EQUILEND 20 HOLDINGS LLC: 21 22 Appeal from an order of the United States District Court for the Southern District of New
23 York (Sullivan, J.).
24 UPON DUE CONSIDERATION, IT IS HEREBY ORDERED, ADJUDGED, AND
25 DECREED that the order of the district court is AFFIRMED.
26 SL-x IP S.à.r.l. (the “Parent Company”) and its four subsidiaries, SL-x Technology UK
27 Limited, SL-x Trading Europe Limited, SL-x Technology USA LLC, and SL-x Trading USA LLC
28 (the “Subsidiary Companies”) (collectively, “SL-x”) filed suits alleging Defendants-Appellees
29 violated federal and state antitrust laws by colluding to force SL-x out of the stock lending market,
30 and asserting state law claims of tortious interference with business relations, unjust enrichment,
31 and violations of New York’s Deceptive Practices Act. SL-x appeals from the order entered on
32 September 30, 2021, by the United States District Court for the Southern District of New York
33 (Sullivan, J.), dismissing the Parent Company’s complaint for lack of Article III standing,
34 dismissing the federal and state antitrust claims in the Subsidiary Companies’ complaint as time-
3 1 barred, and declining to exercise supplemental jurisdiction over the remaining state law claims.
2 For the reasons that follow, we affirm the decision of the district court. We assume the parties’
3 familiarity with the underlying facts, the procedural history of the case, and the issues on appeal,
4 which we discuss only as necessary to explain our decision.
5 I. Background
6 A. The Alleged Antitrust Conspiracy
7 SL-x was a financial technology startup that offered a patented system for comparing and
8 executing stock lending transactions. The Parent Company is a holding company that operated
9 the SL-x business through the Subsidiary Companies.
10 EquiLend is a consortium of financial services institutions. EquiLend facilitates stock
11 loans by providing an electronic bulletin board on which stock loan pricing can be posted, as well
12 as back-end services that assist with the settlement of stock loans. During the relevant time period,
13 Defendants, some of the largest banks in the world, were co-owners of EquiLend and some of their
14 employees served on EquiLend’s Board of Directors.
15 SL-x pitched its services to the individual financial institution Defendants comprising
16 EquiLend as a competitor of EquiLend from 2011 through July of 2014. SL-x alleges that during
17 that time, EquiLend served as a forum that facilitated Defendants’ agreement to collectively
18 boycott SL-x in that representatives of Defendants attended EquiLend meetings where they
19 discussed whether to do business with SL-x. SL-x also alleges that it attempted to pursue business
20 with third parties, but learned that those efforts failed because Defendants threatened and pressured
21 the third parties to prevent them from doing business with SL-x. SL-x claims that because of
22 Defendants’ anticompetitive conduct, it was forced to sell its intellectual property to EquiLend at
23 a steep discount in May of 2015—a sale which EquiLend allegedly pursued so that no other party
4 1 could make use of the technology. SL-x Trading Europe Limited and SL-x Technology UK
2 Limited were dissolved in 2015 and 2016.
3 B. Procedural History
4 On November 1, 2018, the Parent Company sued Defendants, claiming they had colluded
5 to engage in a group boycott of SL-x, in violation of federal and state antitrust laws. The Parent
6 Company also brought state law claims for tortious interference with business relations, unjust
7 enrichment, and violations of New York’s Deceptive Practices Act. Defendants moved to dismiss
8 the complaint on the grounds that the Parent Company lacked standing and that the alleged
9 wrongful acts occurred outside the statute of limitations. 1 The Parent Company revived the
10 Subsidiary Companies—the purported true owners of the claims—but the district court denied its
11 request for leave to assign the claims to the Parent Company or to amend its complaint to join the
12 Subsidiary Companies as plaintiffs.
13 On May 24, 2019, the Subsidiary Companies filed a separate but virtually identical suit.
14 The parties agreed to consolidate the Parent and Subsidiary Companies’ actions and, in accordance
15 with the parties’ agreement, the district court ordered that Defendants’ fully briefed motion to
16 dismiss the Parent Company’s complaint be deemed responsive to the Subsidiary Companies’
17 complaint. As relevant here, the district court dismissed the Parent Company’s complaint for lack
18 of standing and the federal and state antitrust claims in the Subsidiary Companies’ complaint as
19 time-barred. The district court declined to exercise supplemental jurisdiction over the remaining
20 state law claims in the Subsidiary Companies’ complaint due to the dismissal of the federal claims.
21 The Parent and Subsidiary Companies filed notices of appeal on their respective dockets and the
1 Defendant EquiLend Europe also moved to dismiss for lack of personal jurisdiction, which was denied by the district court and is not at issue on appeal.
5 1 appeals were consolidated.
2 II. Discussion
3 A. Statute of Limitations for Antitrust Claims
4 The district court properly dismissed SL-x’s antitrust claims as time-barred because the
5 causes of action accrued outside of the statutory time period. This Court reviews “de novo a
6 district court’s grant of a motion to dismiss, including its legal interpretation and application of a
7 statute of limitations.” DeSuze v. Ammon, 990 F.3d 264, 268 (2d Cir. 2021) (internal quotation
8 marks and citation omitted). “When a district court determines that equitable tolling is
9 inappropriate, we review the legal premises for that conclusion de novo, the factual bases for clear
10 error, and the ultimate decision for abuse of discretion.” Id.
11 SL-x asserted its antitrust claims under the Sherman Act, 15 U.S.C. § 1, the Clayton Act,
12 15 U.S.C. §§ 15 and 15/26" style="color:var(--green);border-bottom:1px solid var(--green-border)">26, and New York’s Donnelly Act, N.Y. Gen. Bus. Law § 340 et seq., each
13 of which has a four-year statute of limitations period. 15 U.S.C. § 15b; N.Y. Gen. Bus. Law §
14 340(5). The Parent Company filed its complaint on November 1, 2018 and the Subsidiary
15 Companies filed their virtually identical complaint on May 24, 2019. The district court treated
16 November 1, 2018 as the relevant filing date; we do the same here. Accordingly, for SL-x’s claims
17 to fall within the statute of limitations, the allegedly conspiratorial acts must have taken place on
18 or after November 1, 2014.
19 A cause of action under the antitrust laws accrues “when a defendant commits an act that
20 injures a plaintiff’s business[,]” but the clock can restart in cases if the conspiracy continues
21 through additional overt acts. Zenith Radio Corp. v. Hazeltine Research, Inc., 401 U.S. 321, 338
22 (1971). “[A]ntitrust law provides that, in the case of a continuing violation, say, a price–fixing
23 conspiracy that brings about a series of unlawfully high priced sales over a period of years, each
6 1 overt act that is part of the violation and that injures the plaintiff, e.g., each sale to the plaintiff,
2 starts the statutory period running again, regardless of the plaintiff’s knowledge of the alleged
3 illegality at much earlier times.” US Airways, Inc. v. Sabre Holdings Corp., 938 F.3d 43, 67 (2d
4 Cir. 2019) (internal quotation marks and citations omitted); see also Zenith, 401 U.S. at 338. “[A]n
5 overt act that restarts the statute of limitations is characterized by two elements: (1) it must be a
6 new and independent act that is not merely a reaffirmation of a previous act; and (2) it must inflict
7 new and accumulating injury on the plaintiff.” US Airways, 938 F.3d at 68 (internal quotation
8 marks and citation omitted).
9 SL-x is incorrect in its contention that the 2015 sale of SL-x’s intellectual property to
10 EquiLend was a new overt act that restarted the statute of limitations period. The EquiLend sale
11 allegedly resulted in a steep discount in price for Defendants because of their prior refusals to
12 engage with SL-x. As the district court reasonably concluded, if SL-x had been forced to sell its
13 patents at a low price to any of the potential third-party investors discussed in the complaint, or if
14 Defendants had opted to not purchase the IP at all, SL-x “would have realized the same injury
15 resulting from Defendants’ earlier anticompetitive conduct.” SL-x IP S.à.r.l. v. Bank of Am. Corp.,
16 No. 18CV10179(RJS), 2021 WL 4523711, at *10 (S.D.N.Y. Sept. 30, 2021). Indeed, based on
17 the allegations in the complaint, SL-x’s sale of its IP to Defendants was merely a “manifestation”
18 of Defendants’ alleged prior agreement to freeze SL-x out of the market. US Airways, 938 F.3d at
19 69; see also Simmons v. Reich, No. 20-4114, 2021 WL 5023354, at *3 (2d Cir. Oct. 29, 2021)
20 (collecting cases and explaining that the limitations period does not restart when events are
21 “derivative,” “symptoms,” or “direct consequences” of earlier wrongdoing). Accordingly, SL-x
22 “ha[s] not shown how any new act could have caused [it] harm over and above the harm that the
23 earlier acts” by Defendants caused it, and therefore, its argument that the 2015 sale was a distinct
7 1 violation for which a separate cause of action accrued fails. Klehr v. A.O. Smith Corp., 521 U.S.
2 179, 190 (1997) (discussing civil RICO cases and explaining that “as in the antitrust cases, the
3 plaintiff cannot use an independent, new predicate act as a bootstrap to recover for injuries caused
4 by other earlier predicate acts that took place outside the limitations period.”).
5 SL-x’s alternative argument is that its antitrust claims did not accrue until the 2015 sale to
6 EquiLend because prior to that time, it was unclear how long the boycott would last and damages
7 could not be measured. In Zenith Radio Corp. v. Hazeltine Research, Inc., the Supreme Court held
8 that “antitrust damages [may be] so ‘speculative’ or ‘unprovable’ at the time of a defendant’s
9 unlawful act (and plaintiff’s initial injury) that to follow the normal accrual rule (starting the
10 limitations period at the point the act first causes injury) would [leave] the plaintiff without relief.”
11 Klehr, 521 U.S. at 190–91 (citing Zenith, 401 U.S. at 339–40). “[I]n such a case, a claim for the
12 injuries that had been speculative would accrue when those injuries occurred, even though the act
13 that caused them had taken place more than four years earlier.” Id. at 191. But the exception
14 created in Zenith applies only in “the rare case in which the damages caused by an antitrust injury
15 are so speculative that the court is unwilling to estimate them.” Higgins v. New York Stock Exch.,
16 Inc., 942 F.2d 829, 832 (2d Cir. 1991). This is not one of those rare cases. The possibility that
17 SL-x might have later sold its intellectual property has no bearing on the fact that damages could
18 have been calculated earlier, for example, when SL-x shut down its business in 2014. Because
19 SL-x’s damages, while perhaps uncertain, were calculable prior to the 2015 sale, this argument
20 likewise fails.
21 Nor was the statute of limitations tolled because the defendants fraudulently concealed the
22 alleged conspiracy.
23 [A]n antitrust plaintiff may prove fraudulent concealment sufficient to toll the 24 running of the statute of limitations if he establishes (1) that the defendant
8 1 concealed from him the existence of his cause of action, (2) that he remained in 2 ignorance of that cause of action until some point within four years of the 3 commencement of his action, and (3) that his continuing ignorance was not 4 attributable to lack of diligence on his part. 5 6 State of N.Y. v. Hendrickson Bros., 840 F.2d 1065, 1083 (2d Cir. 1988); see also Abbas v.
7 Dixon, 480 F.3d 636, 642 (2d Cir. 2007) (“Under New York law, the doctrines of equitable tolling
8 or equitable estoppel may be invoked to defeat a statute of limitations defense when the plaintiff
9 was induced by fraud, misrepresentations or deception to refrain from filing a timely action.”
10 (internal quotation marks and citation omitted)). “[T]he plaintiff may prove the concealment
11 element by showing either that the defendant took affirmative steps to prevent the plaintiff’s
12 discovery of his claim or injury or that the wrong itself was of such a nature as to be self-
13 concealing.” Hendrickson Bros., 840 F.2d at 1083. Equitable tolling applies only in “rare and
14 exceptional circumstance[s],” and it requires that the plaintiff “acted with reasonable diligence
15 throughout the period he seeks to toll.” Smith v. McGinnis, 208 F.3d 13, 17 (2d Cir. 2000) (internal
16 quotation marks omitted); see also Johnson v. Nyack Hosp., 86 F.3d 8, 12 (2d Cir. 1996)
17 (observing that equitable tolling is appropriate when a plaintiff “has been prevented in some
18 extraordinary way from exercising his rights” (internal quotation marks omitted)).
19 Nor was the statute of limitations tolled by reason of the alleged conspiracy. 2 Regardless
2 Specifically, SL-x alleges the following: • On August 7, 2013, a JP Morgan executive told SL-x that “there is general agreement among [EquiLend] Directors that industry advances should be achieved from within EquiLend” and that “JP Morgan participated in discussions with other banks about industry direction at the EquiLend meetings.” J.A. A-84, 606; see also id. at A-89, 611 (“SL-x was told by other market participants that this was due to interference from Goldman Sachs. Key decision-makers at DTCC were ‘in Goldman’s pocket’ and would never consent to providing clearing for SL-x so long as Goldman Sachs opposed it.”). • In February of 2013, it was warned by a Credit Suisse executive that “EquiLend was like ‘the mafia run by five crime families’ and that SL-x should not underestimate it as a competitor.” Id. at A-81, 603. • In July of 2013, the same executive told SL-x that Credit Suisse had changed its mind on its interest in the platform and “would only join after other large players —'the Big Boys’—committed,” and “that without approval from EquiLend, SL-x was unlikely to be able to achieve a foothold in the industry.” Id. at A-81, 603.
9 1 of whether Defendants continued to meet with SL-x after the disclosure, at bottom, SL-x was aware
2 of Defendants’ reluctance to do business with it, was given an explanation for that hesitation, and
3 was told directly by Defendants’ executives about the agreement amongst Defendants to prioritize
4 EquiLend’s success. Accordingly, the alleged conspiracy could not have been “depende[nt] on
5 concealment for its success.” Appellant’s Br. at 35. Thus, we conclude that the district court did
6 not abuse its discretion in concluding that equitable tolling did not apply in this case.
7 For the same reasons, the district court correctly concluded that SL-x was at least on inquiry
8 notice of the alleged agreement. “Inquiry notice requires knowledge of suspicious facts that need
9 not suggest a ‘high probability’ of wrongdoing but are nonetheless sufficient to induce a reasonable
10 person to investigate.” In re Bernard L. Madoff Inv. Sec. LLC, 12 F.4th 171, 185 (2d Cir. 2021)
11 (citing Merck & Co., Inc. v. Reynolds, 559 U.S. 633, 650–51 (2010)). In addition to including in
12 the complaints allegations recounting statements Defendants’ executives made directly to SL-x
13 representatives, SL-x repeatedly highlighted the unusual nature of Defendants’ rejections that
14 occurred between August 2013 and July 2014. 3 Because SL-x has alleged that there were several
15 markers that something was amiss, this is not a “rare and exceptional circumstance” where
16 equitable tolling should be applied. Smith, 208 F.3d at 17. Accordingly, SL-x’s antitrust claims 4
• On September 26, 2013, a UBS executive “explicitly discussed” with SL-x “the benefit of being ‘inside the club’ of EquiLend member banks to effectuate market changes and suggested that any market transition towards an SL- x platform and central clearing of stock loan trades would need to come from inside EquiLend.” Id. at A-86, 608. 3 For example, SL-x describes Defendants’ loss of interest in its product as a “strange reversal,” J.A. A-82, 603, a “sudden[ ] and unexpected[ ] withdr[awal],” id. at A-92, 614, changing “dramatically,” “sudden[ly]” id. at A-84, 606, and “markedly,” id. at 85, 607, and being “strangely and suddenly extinguished,” id. at A-88, 609. 4 The Donnelly Act was modeled on the Sherman Act and “should generally be construed in light of Federal precedent and given a different interpretation only where State policy, differences in the statutory language or the legislative history justify such a result.” Gatt Commc’ns, Inc. v. PMC Assocs., L.L.C., 711 F.3d 68, 81 (2d Cir. 2013) (quoting X.L.O. Concrete Corp. v. Rivergate Corp., 83 N.Y.2d 513, 518 (1994) (internal quotation marks omitted)). We see no reason to interpret the Donnelly Act differently than the Sherman Act in this matter. Accordingly, because SL-x’s federal antitrust claims are time-barred, so too are its Donnelly Act claims. See Biocad JSC v. F. Hoffmann-La Roche, 942 F.3d 88, 101 (2d Cir. 2019) (“As [plaintiff] has not stated a plausible claim for relief under the Sherman Act, its Donnelly Act claim similarly fails.”).
10 1 are barred by the four-year statute of limitations. 5
2 III. Supplemental Jurisdiction
3 We review a district court’s decision not to exercise supplemental jurisdiction over state-
4 law claims for abuse of discretion. Kroshnyi v. U.S. Pack Courier Servs., Inc., 771 F.3d 93, 102
5 (2d Cir. 2014). Having properly dismissed SL-x’s federal claims and state law antitrust claims,
6 the district court did not err in declining to exercise supplemental jurisdiction over the remaining
7 state law claims. 28 U.S.C. § 1367; see Marcus v. AT&T Corp., 138 F.3d 46, 57 (2d Cir. 1998)
8 (“In general, where the federal claims are dismissed before trial, the state claims should be
9 dismissed as well.”).
10 IV. Leave to Amend
11 The district court did not abuse its discretion in denying SL-x leave to amend. Federal
12 Rule of Civil Procedure 15(a)(2) permits a party to amend its complaint with “the court’s leave,”
13 which “should [be] freely give[n] . . . when justice so requires.” Fed. R. Civ. P. 15(a)(2). “We
14 review the denial of leave to amend a complaint under an abuse of discretion standard.” Jin v.
15 Metro. Life Ins. Co., 310 F.3d 84, 101 (2d Cir. 2002). Our review of a district court’s denial of
16 leave to replead “involves the appraisal of numerous factors, and a court of appeals exercises
17 considerable discretion in addressing the question.” Porat v. Lincoln Towers Cmty. Ass’n, 464
18 F.3d 274, 276 (2d Cir. 2006). We conclude that the district court did not err in its denial,
19 “[e]specially given that plaintiff’s counsel did not advise the district court how the complaint’s
20 defects would be cured.” Id. And, while SL-x proposed certain amendments in its reply brief filed
5 Because SL-x’s antitrust claims are time-barred based on the filing date of either the Parent Company’s complaint (November 1, 2018) or the Subsidiary Companies’ complaint (May 24, 2019), we need not reach SL-x’s arguments on whether the Parent Company had Article III standing at the time it filed its complaint. See Headley v. Tilghman, 53 F.3d 472, 476 (2d Cir. 1995) (“We are free to affirm on any ground that finds support in the record[.]”).
11 1 in this Court, those changes do not address the identified flaws in the complaints, but rather are
2 largely conclusory statements describing legal findings it requests that this Court adopt.
3 Accordingly, SL-x has failed to demonstrate how any attempt to replead would not be futile. See
4 Melendez v. Sirius XM Radio, Inc., 50 F.4th 294, 309 (2d Cir. 2022).
5 * * *
6 We have considered all of SL-x’s remaining arguments and find them to be without merit.
7 For the foregoing reasons, we AFFIRM the September 30, 2021 order of the district court.
8 FOR THE COURT: 9 Catherine O’Hagan Wolfe, Clerk of Court